Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169418 | 1.00 | MAPKAPK5 (0.51) | MAPKAPK5MAPK8PTK6AURKAAURKB | |
| SCHEMBL3466854 | 0.76 | TTK (0.53) | MAPK8ADORA3FLT3TTK | |
| SCHEMBL3467078 | 0.76 | TTK (0.51) | MAPK8ADORA3FLT3TTK | |
| SCHEMBL3469551 | 0.74 | FYN (0.57) | MAPK8ADORA3FLT3TTK | |
| SCHEMBL13954830 | 0.73 | AURKB (0.47) | MAPKAPK5PTK6AURKAAURKBFLT3 | |
| SCHEMBL3470503 | 0.72 | MAPK8 (0.44) | MAPK8ADORA3FLT3TTK | |
| SCHEMBL14387387 | 0.72 | MAPKAPK5 (0.45) | MAPKAPK5PTK6AURKAAURKBFLT3 | |
| SCHEMBL1674071 | 0.71 | MAPKAPK5 (0.70) | MAPKAPK5PTK6AURKAAURKB | |
| SCHEMBL5394394 | 0.71 | TTK (0.59) | MAPK8ADORA3FLT3TTK | |
| SCHEMBL10161077 | 0.70 | MAPKAPK5 (0.55) | MAPKAPK5PTK6AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | claimed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | claimed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885MAPK8 691/4885PTK6 2026/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885MAPK8 691/4885PTK6 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.